Macquarie Group
HEPA

Macquarie Group’s Hepion Pharmaceuticals HEPA Stock Holding History

Macquarie Group’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$90 – 1773
2024
Q2 		$90 Hold
2
– – ﹤0.01% 1883
2024
Q1 		$0 Buy
+2
New +$230 ﹤0.01% 1914

Other funds holding HEPA

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Macquarie Group's HEPA Position: Q3 2024 in Review

Macquarie Group sold out of Hepion Pharmaceuticals (HEPA) in Q3 2024, closing a stake of 2 shares — an estimated $90 sold.

Macquarie Group first reported a position in HEPA in Q1 2024 and held it in 2 quarters. The position peaked at $90 in Q2 2024. 16 funds tracked by Wall St. Rank hold HEPA as of Q3 2024.

  • Macquarie Group reported no remaining Hepion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 2 Hepion Pharmaceuticals shares in Q3 2024, an estimated $90.
  • Macquarie Group first reported a position in Hepion Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Macquarie Group's Hepion Pharmaceuticals position peaked at $90 in Q2 2024.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.